Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptatsh1654

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS 18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 19	JAN 25	Annual Reload of MEDLINE database
NEWS 20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features

NEWS 24 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2, AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:28:28 ON 16 MAR 2010

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 15:28:52 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2010 HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES: 15 MAR 2010 HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s KNNE/sqsp
L1 12915 KNNE/SQSP

=> s l1 and sql<=10

```
        852353 SQL<=10
L2          15 L1 AND SQL<=10

=> fil hcap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      38.84      39.06

FILE 'HCAPLUS' ENTERED AT 15:29:41 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Mar 2010  VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010  (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> l2
L3          11 L2

=> d l3 ibib abs hitstr 1-11
```

L3 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1050188 HCAPLUS
DOCUMENT NUMBER: 151:281002
TITLE: Methods and compositions for adeno-associated virus (AAV) with HI loop mutations
INVENTOR(S): Diprimio, Nina; Samulski, Richard Jude
PATENT ASSIGNEE(S): University of North Carolina at Chapel Hill, USA
SOURCE: U.S. Pat. Appl. Publ., 118pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090215879	A1	20090827	US 2009-369945	20090212
WO 2009108274	A2	20090903	WO 2009-US886	20090212
WO 2009108274	A3	20100107		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2008-31581P P 20080226
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention provides modified AAV capsid proteins comprising substitutions in the HI loop. Suitable substitutions include affinity tags, sequences that facilitate detection and/or targeting peptides. The invention also provides virus capsids and virus vectors comprising the modified AAV capsid proteins and methods of using the same. Further provided are methods of purifying the modified AAV capsid subunits, virus capsids and virus vectors of the invention.
IT **1182714-32-4**
RL: PRP (Properties)
(unclaimed protein sequence; methods and compns. for adeno-associated virus (AAV) with HI loop mutations)
RN 1182714-32-4 HCAPLUS
CN L-Tryptophan, L-isoleucyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-methionyl- (CA INDEX NAME)

Absolute stereochemistry.


H
N
HN
S
CO2H
O
S
HN
O
SMe
HN
S
O
HN
S
O
CO2H
O
NH2
HN
S
O
HN
S
O
(CH2)4
NH2
NH2
HN
S
O
S
Et
Me
O
NH2

L3 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:720268 HCAPLUS
Correction of: 2009:592717
DOCUMENT NUMBER: 151:6802
Correction of: 150:512998
TITLE: Multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis
INVENTOR(S): Scholler, Jorgen; Brix, Liselotte; Pedersen, Henrik; Jakobsen, Tina
PATENT ASSIGNEE(S): Dako Denmark A/S, Den.
SOURCE: PCT Int. Appl., 1642pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 27
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009039854	A2	20090402	WO 2008-XD339	20080929

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DK 2007-1395 A 20070927
US 2007-960394P P 20070927

AB The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of. [This abstract record is one of 51 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

IT **1159328-30-9** **1159328-31-0** **1159329-54-0**
1159329-55-1 **1159330-92-3**
RL: PRP (Properties)
(unclaimed protein sequence; multimers of MHC complexed with Mycobacterium tuberculosis peptide as vaccine and for diagnosis, prognosis and therapy of tuberculosis)

RN 1159328-30-9 HCAPLUS
CN L-Phenylalanine, L-threonyl-L-α-glutamyl-L-threonyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 1159328-31-0 HCAPLUS
CN L-Arginine, L-α-glutamyl-L-threonyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-phenylalanyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 1159329-54-0 HCAPLUS
CN L-Arginine, L-threonyl-L-α-glutamyl-L-threonyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-phenylalanyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 1159329-55-1 HCAPLUS
CN L-Valine, L-α-glutamyl-L-threonyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-phenylalanyl-L-arginyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 1159330-92-3 HCAPLUS

CN L-Phenylalanine, L-isoleucyl-L-prolyl-L-threonyl-L-α-glutamyl-L-threonyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L3 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1297675 HCAPLUS
DOCUMENT NUMBER: 149:507515
TITLE: Identification, isolation and therapeutic and diagnostic uses of replikins, peptides related to rapid cell replication and high human mortality
INVENTOR(S): Bogoch, Samuel; Bogoch, Elenore S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 221pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7442761	B2	20081028	US 2004-860050	20040604
US 20050202415	A1	20050915		
AU 2004259640	A1	20050203	AU 2004-259640	20040607
CA 2528440	A1	20050203	CA 2004-2528440	20040607
WO 2005010032	A2	20050203	WO 2004-US17936	20040607
WO 2005010032	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636254	A2	20060322	EP 2004-785929	20040607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007526222	T	20070913	JP 2006-515241	20040607
NZ 544277	A	20090228	NZ 2004-544277	20040607
AU 2005237587	A1	20051110	AU 2005-237587	20050428
CA 2565006	A1	20051110	CA 2005-2565006	20050428
WO 2005104754	A2	20051110	WO 2005-US14443	20050428
WO 2005104754	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20060024669	A1	20060202	US 2005-116203	20050428
EP 1745401	A2	20070124	EP 2005-743059	20050428

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

CN 1947122	A	20070411	CN 2005-80012974		20050428
JP 2007535766	T	20071206	JP 2007-510929		20050428
NZ 550512	A	20080829	NZ 2005-550512		20050428
SG 153065	A1	20090629	SG 2009-3296		20050428
US 20070026009	A1	20070201	US 2006-355120		20060216
KR 2006127253	A	20061211	KR 2006-721152		20061012
US 20090053257	A1	20090226	US 2008-170763		20080710
PRIORITY APPLN. INFO.:			US 2003-476186P	P	20030606
			US 2003-504958P	P	20030923
			US 2003-531686P	P	20031223
			US 2001-278761P	P	20010327
			US 2001-303396P	P	20010709
			US 2001-984057	A2	20011026
			US 2002-105232	A2	20020326
			US 2002-189437	A2	20020708
			US 2004-565847P	P	20040428
			US 2004-860050	A	20040604
			WO 2004-US17936	W	20040607
			US 2005-653083P	P	20050216
			US 2005-116203	A2	20050428
			WO 2005-US14443	W	20050428

AB The present invention provides replikins, a new class of peptides related to rapid cell replication and high human mortality, and their use in diagnosing, preventing and treating disease. An algorithm to search for replikins was constructed. The replikins have from 7 to about 50 amino acids comprising (1) at least one lysine residue located 6-10 residues from a second lysine residue, (2) at least one histidine residues, and (3) at least 6% lysine residues. Replikins have been found in viruses (i.e. coronavirus, influenza virus, SARS virus), bacteria, fungi, cancer associated proteins, plants and unicellular parasites. Extraction, isolation and identification of replikins and the use of replikins to target, label or destroy replikin-containing organisms is described. The amino acid sequences of coronaviral replikins are disclosed. Synthetic replikins were devised for the use as anti-SARS vaccines.

IT **605635-66-3**
RL: PRP (Properties)
(unclaimed protein sequence; identification, isolation and therapeutic and diagnostic uses of replikins, peptides related to rapid cell replication and high human mortality)

RN 605635-66-3 HCAPLUS

CN L-Lysine, L-histidyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-α-aspartyl-L-isoleucyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:817917 HCAPLUS
DOCUMENT NUMBER: 139:322282
TITLE: Replikin peptides and antibodies: diagnosis and therapy
INVENTOR(S): Bogoch, Samuel; Bogoch, Elenore S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 187 pp., Cont.-in-part of U.S. Ser. No. 105,232.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030194414	A1	20031016	US 2002-189437	20020708
US 7452963	B2	20081118		
US 20020151677	A1	20021017	US 2001-984057	20011026
US 7420028	B2	20080902		
US 20030180328	A1	20030925	US 2002-105232	20020326
US 7189800	B2	20070313		
US 20060024669	A1	20060202	US 2005-116203	20050428
US 20070026009	A1	20070201	US 2006-355120	20060216
US 20090137778	A1	20090528	US 2008-252028	20081015

PRIORITY APPLN. INFO.:

US 2001-278761P	P	20010327
US 2001-303396P	P	20010709
US 2001-984057	A2	20011026
US 2002-105232	A2	20020326
US 1994-198139	B2	19940217
US 1998-146755	A2	19980904
US 2001-817144	A2	20010327
US 2002-189437	A2	20020708
US 2003-476186P	P	20030606
US 2003-504958P	P	20030923
US 2003-531686P	P	20031223
US 2004-565847P	P	20040428
US 2004-860050	A2	20040604
US 2005-653083P	P	20050216
US 2005-116203	A2	20050428

AB The authors disclose a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease.
IT **605635-66-3**
RL: PRP (Properties)
(unclaimed sequence; replikin peptides and antibodies, diagnosis and therapy)
RN 605635-66-3 HCAPLUS
CN L-Lysine, L-histidyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-α-aspartyl-L-isoleucyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	64	THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:757014 HCAPLUS
DOCUMENT NUMBER: 139:275721
TITLE: Replikin peptides in rapid replication of glioma cells and in influenza and malaria epidemics
INVENTOR(S): Bogoch, Samuel; Bogoch, Elenore S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 136 pp., Cont.-in-part of U.S. Ser. No. 984,057.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030180328	A1	20030925	US 2002-105232	20020326
US 7189800	B2	20070313		
US 20020151677	A1	20021017	US 2001-984057	20011026
US 7420028	B2	20080902		
US 20030194414	A1	20031016	US 2002-189437	20020708
US 7452963	B2	20081118		
CA 2481232	A1	20031009	CA 2003-2481232	20030325
WO 2003083058	A2	20031009	WO 2003-US8990	20030325
WO 2003083058	A3	20060216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003224758	A1	20031013	AU 2003-224758	20030325
EP 1578922	A2	20050928	EP 2003-721445	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1893966	A	20070110	CN 2003-810902	20030325
US 20060024669	A1	20060202	US 2005-116203	20050428
US 20070026009	A1	20070201	US 2006-355120	20060216
US 20070053916	A1	20070308	US 2006-590852	20061101
US 20090137778	A1	20090528	US 2008-252028	20081015
US 20090191189	A1	20090730	US 2009-412888	20090327
US 20090269333	A1	20091029	US 2009-495306	20090630

PRIORITY APPLN. INFO.:

US 2001-278761P	P	20010327
US 2001-303396P	P	20010709
US 2001-984057	A2	20011026
US 1994-198139	B2	19940217
US 1998-146755	A2	19980904
US 2001-817144	A2	20010327
US 2002-105232	A2	20020326
US 2002-189437	A2	20020708
WO 2003-US8990	W	20030325
US 2003-476186P	P	20030606

US 2003-504958P	P	20030923
US 2003-531686P	P	20031223
US 2004-565847P	P	20040428
US 2004-860050	A2	20040604
US 2005-653083P	P	20050216
US 2005-116203	A2	20050428
US 2006-590852	A3	20061101

AB Peptides of glioma (e.g., malignin), influenza virus hemagglutinin and neuraminidase protein, and Plasmodium falciparum malaria antigen are provided as members of a new family of small peptides related to the phenomenon of rapid replication and designated Replikins. The Replikins have from 7 to about 50 amino acids comprising (1) at least one lysine residue located 6-10 residues from a second lysine residue, (2) at least one histidine residues, and (3) at least 6% lysine residues. Antibodies specific for the peptides, influenza vaccines, malaria vaccines, and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.

IT **605635-66-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(from Plasmodium falciparum; Replikin peptides in rapid replication of glioma cells and in influenza and malaria epidemics)

RN 605635-66-3 HCAPLUS

CN L-Lysine, L-histidyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-α-aspartyl-L-isoleucyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:777966 HCAPLUS
DOCUMENT NUMBER: 137:275674
TITLE: Sequence homologs of HmwA proteins identified in non-typable Haemophilus influenzae with possible therapeutic uses
INVENTOR(S): Thonnard, Joelle
PATENT ASSIGNEE(S): Glaxosmithkline Biologicals S.A., Belg.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079237	A2	20021010	WO 2002-EP3210	20020312
WO 2002079237	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440874	A1	20021010	CA 2002-2440874	20020312
AU 2002315262	A1	20021015	AU 2002-315262	20020312
EP 1370577	A2	20031217	EP 2002-740433	20020312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040171805	A1	20040902	US 2004-472078	20040402
PRIORITY APPLN. INFO.:			GB 2001-6155 A	20010313
			GB 2001-6156 A	20010313
			WO 2002-EP3210 W	20020312

AB The invention provides BASB223 and BASB224 polypeptides and polynucleotides encoding BASB223 and BASB224 polypeptides and methods for producing such polypeptides by recombinant techniques. These proteins are sequence homologs of HmwA proteins. Also provided are diagnostic, prophylactic and therapeutic uses.

IT **466687-73-0** **466688-47-1**
RL: PRP (Properties)
(unclaimed sequence; sequence homologs of HmwA proteins identified in non-typable Haemophilus influenzae with possible therapeutic uses)

RN 466687-73-0 HCAPLUS
CN L-Lysine, glycyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 466688-47-1 HCAPLUS
CN L-Glutamic acid, L-valyl-L-lysyl-L-phenylalanyl-L-tyrosylglycyl-L-lysyl-L-asparaginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:483753 HCAPLUS
DOCUMENT NUMBER: 135:317094
TITLE: Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding
AUTHOR(S): Brusic, V.; Bucci, K.; Schonbach, C.; Petrovsky, N.; Zeleznikow, J.; Kazura, J. W.
CORPORATE SOURCE: Kent Ridge Digital Labs, BIC-KRDL, Singapore
SOURCE: Journal of Molecular Graphics & Modelling (2001), 19(5), 405-411
CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Peptides that induce and recall T-cell responses are called T-cell epitopes. T-cell epitopes may be useful in a subunit vaccine against malaria. Computer models that simulate peptide binding to MHC are useful for selecting candidate T-cell epitopes since they minimize the number of expts. required for their identification. The authors applied a combination of computational and immunol. strategies to select candidate T-cell epitopes. A total of 86 exptl. binding assays were performed in three rounds of identification of HLA-A11 binding peptides from the six pre-erythrocytic malaria antigens. Thirty-six peptides were exptl. confirmed as binders. The authors show that the cyclical refinement of the ANN models results in a significant improvement of the efficiency of identifying potential T-cell epitopes.

IT **368859-71-6**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cyclical refinement of QSAR models predict HLA-A11-restricted T-cell epitopes of)
RN 368859-71-6 HCAPLUS
CN L-Lysine, L-lysyl-L-threonyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-asparaginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:435104 HCAPLUS
DOCUMENT NUMBER: 135:40999
TITLE: Complementary peptide ligands generated from microbial genome sequences
INVENTOR(S): Roberts, Gareth Wyn; Heal, Jonathan Richard
PATENT ASSIGNEE(S): Proteom Limited, UK
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042278	A2	20010614	WO 2000-GB4778	20001213
WO 2001042278	A3	20011108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20030199011	A1	20031023	US 2000-573822	20000518
EP 1237905	A2	20020911	EP 2000-981489	20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: GB 1999-29466 A 19991213
WO 2000-GB4778 W 20001213
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention relates to the identification of complementary peptides from the anal. of protein and nucleotide sequence databases from the microbial genomes including pathogenic microbes. These specific complementary peptides interact with their relevant target proteins encoded in the microbial genome. Specific complementary peptides to the proteins encoded in the microbial genome can be used as reagents and drugs from drug discovery programs and as lead ligands to facilitate drug design and development.
IT **344601-35-0**
RL: PRP (Properties)
(unclaimed sequence; complementary peptide ligands generated from microbial genome sequences)
RN 344601-35-0 HCAPLUS
CN L-Glutamic acid, L-α-glutamyl-L-isoleucyl-L-leucyl-L-lysyl-L-isoleucyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:12663 HCAPLUS
DOCUMENT NUMBER: 134:85124
TITLE: Cancer associated antigens and uses therefor
INVENTOR(S): Sahin, Ugur; Tureci, Ozlem; Pfreundschuh, Michael
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000874	A2	20010104	WO 2000-US17207	20000623
WO 2001000874	A3	20020502		
W: AU, CA, CN, JP, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1218538	A2	20020703	EP 2000-941644	20000623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003527826	T	20030924	JP 2001-506864	20000623

PRIORITY APPLN. INFO.: US 1999-346498 A 19990630
WO 2000-US17207 W 20000623

AB Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in testis cells using antisera from seminoma patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with a variety of cancers. The invention provides, inter alia, isolated nucleic acid mols., expression vectors containing those mols. and host cells transfected with those mols. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing mols. addnl. are provided. The mols. provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

IT **317804-03-8** **317804-04-9**
RL: PRP (Properties)
(unclaimed sequence; cancer associated antigens and uses therefor)

RN 317804-03-8 HCAPLUS
CN L-Valine, L-tryptophyl-L-leucyl-L-leucyl-L-valyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 317804-04-9 HCAPLUS
CN L-Valine, L-leucyl-L-leucyl-L-valyl-L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:626211 HCAPLUS
DOCUMENT NUMBER: 131:267042
TITLE: Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease
INVENTOR(S): Watts, Colin
PATENT ASSIGNEE(S): University of Dundee, UK
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9948910	A1	19990930	WO 1999-GB963		19990326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2323063	A1	19990930	CA 1999-2323063		19990326
AU 9931582	A	19991018	AU 1999-31582		19990326
AU 756356	B2	20030109			
EP 1066315	A1	20010110	EP 1999-913464		19990326
EP 1066315	B1	20080528			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK					
JP 2002507623	T	20020312	JP 2000-537892		19990326
IL 138048	A	20060312	IL 1999-138048		19990326
AT 397011	T	20080615	AT 1999-913464		19990326
IN 2000MN00384	A	20050715	IN 2000-MN384		20000908
PRIORITY APPLN. INFO.:			GB 1998-6442	A	19980326
			US 1998-86966P	P	19980528
			WO 1999-GB963	W	19990326

AB A method of modulating the immune response in a patient in need of such modulation comprises administering to the patient an effective amount of an inhibitor of asparaginyl endopeptidase. A method of reducing the processing of a protein antigen by a MHC Class II mol. by a cell comprises contacting the cell with an inhibitor of asparaginyl endopeptidase.

IT **245036-47-9D**, amino- and carboxyl-terminal-blocked
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(asparaginyl endopeptidase inhibitors for immunomodulators)

RN 245036-47-9 HCAPLUS
CN L-α-Glutamine, L-lysyl-L-asparaginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:24490 HCAPLUS
DOCUMENT NUMBER: 130:195463
TITLE: An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation
AUTHOR(S): Manoury, Benedicte; Hewitt, Eric W.; Morrice, Nick; Dando, Pam M.; Barrett, Alan J.; Watts, Colin
CORPORATE SOURCE: Department of Biochemistry, Wellcome Sciences Building, University of Dundee, Dundee, DD1 5EH, UK
SOURCE: Nature (London) (1998), 396(6712), 695-699
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Macmillan Magazines
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Foreign protein antigens must be broken down within endosomes or lysosomes to generate suitable peptides that will form complexes with class II major histocompatibility complex mols. for presentation to T cells. However, it is not known which proteases are required for antigen processing. To investigate this, the authors exposed a domain of the microbial tetanus toxin antigen (TTCF) to disrupted lysosomes that had been purified from a human B-cell line. Here the authors show that the dominant processing activity is not one of the known lysosomal cathepsins, which are generally believed to be the principal enzymes involved in antigen processing, but is instead an asparagine-specific cysteine endopeptidase. This enzyme seems similar or identical to a mammalian homolog of the legumain/hemoglobinase asparaginyl endopeptidases found originally in plants and parasites. The authors designed competitive peptide inhibitors of B-cell asparaginyl endopeptidase (AEP) that specifically block its proteolytic activity and inhibit processing of TTCF in vitro. In vivo, these inhibitors slow TTCF presentation to T cells, whereas preprocessing of TTCF with AEP accelerates its presentation, indicating that this enzyme performs a key step in TTCF processing. The authors also show that N-glycosylation of asparagine residues blocks AEP action in vitro. This indicates that N-glycosylation could eliminate sites of processing by AEP in mammalian proteins, allowing preferential processing of microbial antigens.
IT **220701-07-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(as inhibitor of asparaginyl endopeptidase of human B-cell)
RN 220701-07-5 HCAPLUS
CN L-α-Glutamine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-L-asparaginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	179	THERE ARE 179 CAPLUS RECORDS THAT CITE THIS RECORD (179 CITINGS)
REFERENCE COUNT:	21	THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      66.82     105.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -9.35      -9.35

FILE 'REGISTRY' ENTERED AT 15:30:34 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l1 and sql<=20
       4969317 SQL<=20
L4          78 L1 AND SQL<=20

=> fil hcap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.99     111.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -9.35

FILE 'HCAPLUS' ENTERED AT 15:30:54 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 15:28:28 ON 16 MAR 2010)

     FILE 'REGISTRY' ENTERED AT 15:28:52 ON 16 MAR 2010
L1         12915 S KNNE/SQSP
L2            15 S L1 AND SQL<=10

     FILE 'HCAPLUS' ENTERED AT 15:29:41 ON 16 MAR 2010
L3            11 L2

     FILE 'REGISTRY' ENTERED AT 15:30:34 ON 16 MAR 2010
L4            78 S L1 AND SQL<=20

     FILE 'HCAPLUS' ENTERED AT 15:30:54 ON 16 MAR 2010

=> l4 and (pd<19980101)
             28 L4
      19153499 PD<19980101
                  (PD<19980101)
L5            3 L4 AND (PD<19980101)

=> d l5 ibib abs hitstr 1-3
```

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:24490 HCAPLUS
DOCUMENT NUMBER: 130:195463
TITLE: An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation
AUTHOR(S): Manoury, Benedicte; Hewitt, Eric W.; Morrice, Nick; Dando, Pam M.; Barrett, Alan J.; Watts, Colin
CORPORATE SOURCE: Department of Biochemistry, Wellcome Sciences Building, University of Dundee, Dundee, DD1 5EH, UK
SOURCE: Nature (London) (**1998**), 396(6712), 695-699
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Macmillan Magazines
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Foreign protein antigens must be broken down within endosomes or lysosomes to generate suitable peptides that will form complexes with class II major histocompatibility complex mols. for presentation to T cells. However, it is not known which proteases are required for antigen processing. To investigate this, the authors exposed a domain of the microbial tetanus toxin antigen (TTCF) to disrupted lysosomes that had been purified from a human B-cell line. Here the authors show that the dominant processing activity is not one of the known lysosomal cathepsins, which are generally believed to be the principal enzymes involved in antigen processing, but is instead an asparagine-specific cysteine endopeptidase. This enzyme seems similar or identical to a mammalian homolog of the legumain/hemoglobinase asparaginyl endopeptidases found originally in plants and parasites. The authors designed competitive peptide inhibitors of B-cell asparaginyl endopeptidase (AEP) that specifically block its proteolytic activity and inhibit processing of TTCF in vitro. In vivo, these inhibitors slow TTCF presentation to T cells, whereas preprocessing of TTCF with AEP accelerates its presentation, indicating that this enzyme performs a key step in TTCF processing. The authors also show that N-glycosylation of asparagine residues blocks AEP action in vitro. This indicates that N-glycosylation could eliminate sites of processing by AEP in mammalian proteins, allowing preferential processing of microbial antigens.

IT **220701-07-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(as inhibitor of asparaginyl endopeptidase of human B-cell)
RN 220701-07-5 HCAPLUS
CN L-α-Glutamine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-L-asparaginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	179	THERE ARE 179 CAPLUS RECORDS THAT CITE THIS RECORD (179 CITINGS)
REFERENCE COUNT:	21	THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:638572 HCAPLUS
DOCUMENT NUMBER: 125:301596
ORIGINAL REFERENCE NO.: 125:56463a,56466a
TITLE: Role of isoelectric point and hydrophobicity index of the sequence in synthesis of multiple antigen peptides
AUTHOR(S): Yadav, Satya P.
CORPORATE SOURCE: Biotechnology Support Facility, University Kansas, Kansas City, KS, 66160, USA
SOURCE: Biochemical Archives (**1996**), 12(3), 187-194
CODEN: BIAREM; ISSN: 0749-5331
PUBLISHER: MBR Press, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Multiple Antigen Peptides (MAPs) in length from 7- to 18-mer were synthesized on a multiple peptide synthesizer and characterized by amino acid anal. The amino acid compns. of MAPs were in good agreement with their sequences. The yield of MAPs (nmoles) is significantly correlated to the pI of peptides. The correlation coefficient of nmoles yield of MAPs vs pI was 0.66, while the correlation coefficient between hydrophobicity index and the nmoles yield of MAP is - 0.60.
IT **183024-18-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(role of isoelec. point and hydrophobicity index in preparation of multiple antigen peptides)
RN 183024-18-2 HCAPLUS
CN β-Alanine, N-[N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[N2-[N2-[N2-[N-[1-[N-[N-[N2-[N2-(N2-L-seryl-L-lysyl)-L-asparaginyl]-L-asparaginyl]-L-α-glutamyl]-L-seryl]-L-prolyl]-L-threonyl]-L-arginyl]-L-glutaminyl]-L-lysyl]-L-leucyl]-L-lysyl]-L-lysyl]-L-lysyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:189989 HCAPLUS
DOCUMENT NUMBER: 122:1061
ORIGINAL REFERENCE NO.: 122:255a,258a
TITLE: Synthetic fibronectin fragments as inhibitors of retroviral infections
INVENTOR(S): Wahl, Sharon M.; Mccarthy, James B.; Furcht, Leo T.
PATENT ASSIGNEE(S): Regents of the University of Minnesota, USA; United States Dept. of Health and Human Services
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417097	A1	19940804	WO 1994-US729	19940119 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5545620	A	19960813	US 1994-291349	19940816 <--

PRIORITY APPLN. INFO.: US 1993-6121 A 19930119

AB Retroviral infections, e.g. by HIV, are inhibited using conjugates of defined fragments of fibronectins to carriers such as ovalbumin. These conjugates may be used in conjunction with anti-retroviral antibiotics. The ability of these conjugates to inhibit retrovirus replication in cell culture is demonstrated.

IT **158923-03-6D**, conjugates with ovalbumin
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; synthetic fibronectin fragments as inhibitors of retroviral infections)

RN 158923-03-6 HCAPLUS
CN L-Threonine, L-lysyl-L-asparaginyl-L-asparaginyl-L-α-glutamyl-L-lysyl-L-seryl-L-α-glutamyl-L-prolyl-L-leucyl-L-isoleucylglycyl-L-arginyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      26.75     138.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.55     -11.90

FILE 'REGISTRY' ENTERED AT 15:33:27 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.39     144.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -11.90

FILE 'REGISTRY' ENTERED AT 15:40:10 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.
```

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\09646950\Claim 20.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25
chain bonds :
1-2 1-3 1-4 4-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-13 13-14 13-16
14-15 14-20 16-17 17-18 17-19 20-21 21-22 21-24 22-23 22-25
exact/norm bonds :
1-2 1-4 4-5 6-7 6-8 8-9 10-11 10-12 12-13 14-15 14-20 17-18 17-19
20-21 21-24 22-23 22-25
exact bonds :
1-3 5-6 9-10 13-14 13-16 16-17 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom

L6 STRUCTURE UPLOADED

=> dis

L6 HAS NO ANSWERS
L6 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l6 sss full
FULL SEARCH INITIATED 15:40:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L6

=>
Uploading C:\Program Files\Stnexp\Queries\09646950\Claim 20a.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 27
chain bonds :
1-2 1-3 1-27 3-4 4-5 5-6 5-7 7-8 8-9 9-10 9-11 11-12 12-13 12-15
13-14 13-19 15-16 16-17 16-18 19-20 20-21 20-23 21-22 21-24
exact/norm bonds :
1-2 1-3 1-27 3-4 5-6 5-7 7-8 9-10 9-11 11-12 13-14 13-19 16-17 16-18
19-20 20-23 21-22 21-24
exact bonds :
4-5 8-9 12-13 12-15 15-16 20-21

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 27:Atom

L8 STRUCTURE UPLOADED

=> dis
L8 HAS NO ANSWERS
L8 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l8 sss full
FULL SEARCH INITIATED 15:41:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L9 0 SEA SSS FUL L8

=>
Uploading C:\Program Files\Stnexp\Queries\09646950\Claim 20b.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 27
chain bonds :
1-2 1-3 1-27 3-4 4-5 5-6 5-7 7-8 8-9 9-10 9-11 11-12 12-13 12-15 13-14 13-19 15-16 16-17 16-18 19-20 20-21 20-23 21-22 21-24
exact/norm bonds :
1-2 1-3 1-27 3-4 5-6 5-7 7-8 9-10 9-11 11-12 13-14 13-19 16-17 16-18 19-20 20-23 21-22 21-24
exact bonds :
4-5 8-9 12-13 12-15 15-16 20-21

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 27:Atom

L10 STRUCTURE UPLOADED

=> s l10 sss full
FULL SEARCH INITIATED 15:43:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L10

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	575.60	719.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-11.90

FILE 'REGISTRY' ENTERED AT 15:43:06 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2010 HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES: 15 MAR 2010 HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s NC/sqep
18 NC/SQEP
3490 SQL=2

```
L12         18 NC/SQEP
                (NC/SQEP AND SQL=2)

=> fil hcap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       8.34     727.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -11.90

FILE 'HCAPLUS' ENTERED AT 15:43:46 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Mar 2010  VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010  (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> l12
L13         13 L12

=> d l13 ibib abs hitstr 1-13
```

L13 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1298870 HCAPLUS
DOCUMENT NUMBER: 147:362876
TITLE: Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups
AUTHOR(S): Chua, Brendon Y.; Zeng, Weiguang; Lau, Yuk Fai; Jackson, David C.
CORPORATE SOURCE: Cooperative Research Centre for Vaccine Technology, Department of Microbiology and Immunology, The University of Melbourne, Parkville, 3010, Australia
SOURCE: Vaccine (2007), 25(1), 92-101
CODEN: VACCDE; ISSN: 0264-410X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have previously shown that incorporating the lipid moiety dipalmitoyl-S-glyceryl cysteine (Pam2Cys) into peptide structures effectively adjuvants otherwise weak immunogens. In this study lipopeptides based on LH releasing hormone (LHRH) as a B cell epitope, [B], were synthesized in tandem with a 17-residue T-helper epitope, [T], derived from the fusion protein of the morbillivirus canine distemper virus. In this way vaccine candidates with the structure [T]-[B] were produced. These peptides were then lipidated with different diacylated moieties. The acyl moieties used were: palmitic acid (C16) to give Pam2Cys, stearic acid (C18) to give Ste2Cys, lauric acid (C12) to give Lau2Cys and octanoic acid (C8) to give Oct2Cys. We compared the immunogenicities of these simple lipopeptides in BALB/c mice by measuring their ability to induce anti-LHRH antibodies and found that immunogenicity was dependent on the length of the alkane chains of the incorporated lipid moieties with the hierarchy C16 = C18 > C12 > C8. The antibody levels elicited by the lipopeptides also correlated with their ability to inhibit the reproductive capability of female mice in fertility trials. Furthermore, the C16 lipopeptide was the most effective in activating dendritic cells, measured by up regulation of surface MHC Class II mols., and also in activating NF-κB in a Toll-like receptor-2 (TLR2)-dependent manner.

IT **949112-58-7P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(lipopeptide-based immunocontraceptive vaccines containing LHRH and T-helper peptides)
RN 949112-58-7 HCAPLUS
CN Glycinamide, L-lysyl-L-leucyl-L-isoleucyl-L-prolyl-L-asparaginyl-L-alanyl-L-seryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-threonyl-L-lysyl-L-alanyl-L-α-glutamyl-L-leucyl-N6-[S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyl-6-aminohexanoyl]-L-lysyl-5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:558785 HCAPLUS
DOCUMENT NUMBER: 145:69756
TITLE: Erythropoietin receptor-binding peptides, peptide derivatives, and dimers for treatment of diseases
INVENTOR(S): Holmes, Christopher P.; Yin, Qun; Zemede, Genet; Bhandari, Ashok; Dong, Yaohua S.; Tumelty, David; Lalonde, Guy; Palani, Balu; Schatz, Peter J.; Wrighton, Nicholas C.; Dower, William J.; Frederick, Brian T.; Chakrabarti, Anjan
PATENT ASSIGNEE(S): Affymax, Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006062685	A2	20060615	WO 2005-US41112	20051111
WO 2006062685	A3	20061019		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080108564	A1	20080508	US 2007-735106	20070413
PRIORITY APPLN. INFO.:			US 2004-627432P	P 20041111
			US 2005-271524	B1 20051110
			US 2006-497547	A1 20060731

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to peptide compds. that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compds. to treat disorders associated with insufficient or defective red blood cell production Pharmaceutical compns., which comprise the peptide compds. of the invention, are also provided.

IT **890142-41-3**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(erythropoietin receptor-binding peptides, pharmaceutical compns., and therapeutic use)

RN 890142-41-3 HCAPLUS

CN L-Lysinamide, 17N6,17'N6-[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]imino]bis(1-oxo-2,1-ethanediyl)]bis[N-acetyl-L-α-aspartyl-L-tyrosyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-phenylalanylglycyl-L-prolyl-L-leucyl-L-threonyl-L-tryptophyl-L-valyl-L-cysteinyl-L-arginyl-L-prolyl-L-seryl-, cyclic (4→13),(4'→13')-bis(disulfide) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:542290 HCAPLUS
DOCUMENT NUMBER: 145:55979
TITLE: Peptides that bind to the erythropoietin receptor, pharmaceutical compositions, and therapeutic use
INVENTOR(S): Holmes, Christopher P.; Yin, Qun; Zemede, Genet; Bhandari, Ashok; Dong, Yaohua S.; Tumelty, David; Lalonde, Guy; Palani, Balu; Schatz, Peter J.; Wrighton, Nicholas C.; Dower, William J.; Frederick, Brian T.; Chakrabarti, Anjan
PATENT ASSIGNEE(S): Affymax, Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060148	A2	20060608	WO 2005-US41113	20051111
WO 2006060148	A3	20061005		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005310189	A1	20060608	AU 2005-310189	20051111
CA 2587382	A1	20060608	CA 2005-2587382	20051111
EP 1814910	A2	20070808	EP 2005-851595	20051111
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008519858	T	20080612	JP 2007-541390	20051111
MX 2007005777	A	20070720	MX 2007-5777	20070511
IN 2007KN01986	A	20070810	IN 2007-KN1986	20070601
NO 2007002888	A	20070809	NO 2007-2888	20070606
KR 2007108140	A	20071108	KR 2007-713156	20070611
CN 101142234	A	20080312	CN 2005-80046227	20070709
US 20090005292	A1	20090101	US 2008-718998	20080116

PRIORITY APPLN. INFO.: US 2004-627433P P 20041111
WO 2005-US41113 W 20051111
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention provides peptide compds. that are agonists of the erythropoietin receptor. The invention further provides therapeutic methods using such peptide compds. to treat disorders associated with insufficient or defective red blood cell production Pharmaceutical compns. which comprise the peptide compds. are also provided.
IT **890142-41-3**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)
(erythropoietin receptor-binding peptides, pharmaceutical compns., and therapeutic use)
RN 890142-41-3 HCAPLUS
CN L-Lysinamide, 17N6,17'N6-[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]imino]bis(1-oxo-2,1-ethanediyl)]bis[N-acetyl-L-α-aspartyl-L-tyrosyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-phenylalanylglycyl-L-prolyl-L-leucyl-L-threonyl-L-tryptophyl-L-valyl-L-cysteinyl-L-arginyl-L-prolyl-L-seryl-, cyclic (4→13),(4'→13')-bis(disulfide) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:288768 HCAPLUS
DOCUMENT NUMBER: 133:84482
TITLE: Metabolism of desmopressin ([8-D-arginine]deaminovasopressin) by the enzymes of gastrointestinal tract
AUTHOR(S): Barth, Tomislav; Velek, Jiri; Barthova, Jana; Velkova, Vlasta; Jezek, Jan; Hauzerova, Linda; Kasicka, Vaclav; Ubik, Karel; Machova, Alena; Vilhardt, Hans
CORPORATE SOURCE: Institute of Organic Chemistry and Biochemistry, Prague, Czech Rep.
SOURCE: Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (1999), Meeting Date 1998, 862-863. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Akademiai Kiado: Budapest, Hung.
CODEN: 68WKAY
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Desmopressin ([8-D-arginine]deaminovasopressin) is a synthetic peptide known for its prolonged antidiuretic effect, which has been attributed to its strong metabolic stability. The aim of this study was to characterize the interactions of desmopressin with a number of gastrointestinal enzymes and to synthesize and characterize expected desmopressin degradation peptides (which are then further stabilized against enzymic degradation). The results revealed that only the treatment of desmopressin by chymotrypsin resulted in the destruction of the peptide, while treatment with endoprolylpeptidase showed only a slight decrease in biol. potency, and treatment with pepsin revealed no decrease in potency. Five expected desmopressin degradation peptides were synthesized and then characterized (using the antidiuretic biol. assay), and the results showed that none of the compds. was biol. potent (up to doses of 5 μmoles per kg/bw). The results also revealed that in the in vitro assay (isolated rat uterus), no compound had any agonistic or antagonistic effect. In conclusion, the expected products of chymotryptic degradation of desmopressin were synthesized, subjected to physicochem. anal. and biol. evaluation and were shown to be devoid of the antidiuretic properties of desmopressin.

IT **281198-09-2P 281198-10-5P 281198-11-6P**
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(desmopressin metabolism by enzymes of gastrointestinal tract and antidiuretic properties of synthesized desmopressin degradation peptides)

RN 281198-09-2 HCAPLUS
CN Glycinamide, L-phenylalanyl-L-asparaginyl-3-[[3-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-oxopropyl]dithio]-L-alanyl-L-prolyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 281198-10-5 HCAPLUS
CN Glycinamide, L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-D-arginyl-, (3→1')-disulfide with N-(3-mercapto-1-oxopropyl)-L-tyrosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 281198-11-6 HCAPLUS
CN Glycinamide, 5-oxo-L-prolyl-L-asparaginyl-L-cysteinyl-L-prolyl-D-arginyl-, (3→1')-disulfide with N-(3-mercapto-1-oxopropyl)-L-tyrosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:416503 HCAPLUS
DOCUMENT NUMBER: 131:180065
TITLE: Synthetic insulin fragment with insulin-like biological activity
AUTHOR(S): Prozorovskiy, V. N.; Maksimova, E. M.; Alekseeva, A. E.; Grebenschikova, O. G.; Abakumova, O. Yu.; Kutsenko, N. G.; Ivanov, A. S.; Kniazhev, V. N.; Archakov, A. I.
CORPORATE SOURCE: Institute of Biomedical Chemistry, Russian Academy of Medical Science, Moscow, 119832, Russia
SOURCE: Biochemistry and Molecular Biology International (1999), 47(6), 957-963
CODEN: BMBIES; ISSN: 1039-9712
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An insulin fragment, representing the C-terminal functionally important site of its mol. and responsible for receptor binding, was synthesized. The fragment consists of two peptides: a dipeptide (A 20-21) and an octapeptide (B 19-26), linked with a disulfide bond (A20 - B19). The biol. activity of the newly synthesized fragment relative to insulin was assayed for the influence on glycogenesis and for the ability to stimulate glucose uptake. Comparative tests for the biol. activity of the synthesized fragment and of the intact hormone allowed us to conclude that the fragment has insulin-like properties.

IT **240488-51-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthetic insulin fragment with insulin-like biol. activity)
RN 240488-51-1 HCAPLUS
CN L-Tyrosine, L-cysteinylglycyl-L-α-glutamyl-L-arginylglycyl-L-phenylalanyl-L-phenylalanyl-, (1→2')-disulfide with L-asparaginyl-L-cysteine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH2

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1994:580178 HCAPLUS
DOCUMENT NUMBER: 121:180178
ORIGINAL REFERENCE NO.: 121:32739a,32742a
TITLE: Synthesis of disulfide-bridged fragments of ω-conotoxins GVIA and MVIIA: use of Npys as a protecting/activating group for cysteine in Fmoc syntheses
AUTHOR(S): Simmonds, Robin G.; Tupper, David E.; Harris, John R.
CORPORATE SOURCE: Lilly Res. Cent. Ltd., Eli Lilly and Co., Windlesham/Surrey, UK
SOURCE: International Journal of Peptide & Protein Research (1994), 43(4), 363-6
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:180178
GI



AB The 3-nitro-2-pyridinesulfenyl (Npys) moiety is finding increasing utility as a protecting-activating group for cysteine, particularly in the synthesis of cyclic and unsym. disulfides using the Boc strategy. This chemical has been extended to peptides assembled by the Fmoc strategy. N-terminal Cys(Npys) is introduced via Boc-Cys(Npys)-OPfp. Non-N-terminal Cys(Npys) is incorporated by reacting a resin-bound, fully protected Cys(Acm) peptide with NpysCl. This approach has been applied to the synthesis of disulfide-bridged fragments I, II, III and IV of ω-conotoxins GVIA and MVIIA.

IT **157675-23-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, nitropyridinesulfenyl group as protecting/activating group for)

RN 157675-23-5 HCAPLUS
CN L-Argininamide, N-acetyl-L-tyrosyl-L-asparaginyl-S-[(acetylamino)methyl]-L-

cysteinyl-L-cysteinyl-, (4→1')-disulfide with
L-cysteinyl-L-lysinamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L13 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:162824 HCAPLUS
DOCUMENT NUMBER: 118:162824
ORIGINAL REFERENCE NO.: 118:27777a,27780a
TITLE: Synthesis and characterization of a disulfide bond isomer of omega-conotoxin GVIA
AUTHOR(S): Pennington, M. W.; Festin, S. M.; Maccecchini, M. L.; Kem, W. R.
CORPORATE SOURCE: Dep. Pept. Chem., BACHEM Biosci. Inc., Philadelphia, PA, 19104, USA
SOURCE: Toxicon (1992), 30(7), 755-64
CODEN: TOXIA6; ISSN: 0041-0101
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Solid phase peptide synthesis and air oxidation of ω-conotoxin GVIA yielded, in addition to the desired product, an isomeric peptide which could be completely separated from the native toxin by repeated HPLC. A chymotrypsin-trypsin digest of this peptide, when subjected to HPLC peptide mapping, provided peptides identical with synthetic disulfide containing peptides predicted for the ω-conotoxin isomer containing C1-C2, C3-C5, C4-C6 cystinyl pairings. The shaking potency (ED50 = 1500 pmoles/kg, i.c.v.) of the isomeric peptide upon cannulated rats was 1.3% of the potency of native conotoxin (ED50 = 20 pmol/kg). Considering that all three disulfide pairings in the isomer are different from the native toxin, its retention of biol. activity is of interest.

IT **146663-72-1 146663-73-2 146663-74-3**
RL: PROC (Process)
(isolation of, during oxidation and preparation of native toxin)

RN 146663-72-1 HCAPLUS
CN L-Tyrosine, L-seryl-L-cysteinyl-L-asparaginyl-trans-4-hydroxy-L-prolyl-, (2→2')-disulfide with L-asparaginyl-L-cysteinyl-L-cysteinyl-L-arginine (3'→1'')-disulfide with L-cysteinyl-L-tyrosinamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 146663-73-2 HCAPLUS
CN ω-Conotoxin G VIA (reduced), [seco-22/23]-23-de-L-threonine-24-de-L-lysine-25-de-L-arginine-, cyclic (1→8),(15→19)-bis(disulfide), (16→26)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-A



RN 146663-74-3 HCAPLUS
CN L-Arginine, L-asparaginyl-L-cysteinyl-L-cysteinyl-, (2→1')-disulfide with L-cysteinyl-L-tyrosinamide, (3→1'')-disulfide with L-cysteinyl-L-lysine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L13 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1992:592304 HCAPLUS
DOCUMENT NUMBER: 117:192304
ORIGINAL REFERENCE NO.: 117:33243a,33246a
TITLE: Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids
AUTHOR(S): Manning, Maurice; Przybylski, Jozef; Grzonka, Zbigniew; Nawrocka, Eleonora; Lammek, Bernard; Misicka, Aleksandra; Cheng, Ling Ling; Chan, W. Y.; Wo, Nga Ching; Sawyer, Wilbur H.
CORPORATE SOURCE: Dep. Biochem. Mol. Biol., Med. Coll. Ohio, Toledo, OH, 43699-0008, USA
SOURCE: Journal of Medicinal Chemistry (1992), 35(21), 3895-904
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The solid-phase synthesis and antagonistic potencies of 25 β-mercapto-β,β-pentamethylenepropionic acid arginine-vasopressin (AVP) analogs I [X = D-Tyr(Et), D-Phe, D-Ile, D-Leu; X1 = Val, Ile; X2 = bond, Pro, Pro-Arg, Pro-Arg-Gly, Arg-Gly; R = H, H-Arg, H-D-Arg, H-Gly, H-Orn, H-D-Orn, H-D-Lys, H-Arg-Arg, H-Val, H-D-Val] are reported. All 25 peptides were examined for agonistic and antagonistic potencies in AVP antidiuretic (V2) and vasopressor (V1a) receptor assays. With the exception of peptides I (X = D-Ile, D-Leu, X1 = Val, X2 = bond, R = H-Arg), all I exhibit potent anti-V1a antagonism, with anti-V1a pA2 values in the range 7.64-8.33. Comparison of the anti-V2 potencies of peptides I [X = D-Tyr(Et), Tyr(Et), D-Phe, D-Ile, D-Leu, X1 = Val, X2 = bond, R = H, H-Arg] clearly shows the superiority of the D-Tyr(Et)2 substitution in leading to retention and enhancement of V2 antagonism in this series. With only one exception, the retro modified peptides I exhibit either full retention and in a number of cases a 1.5-7.5-fold enhancement of V2 antagonism compared to their resp. parent C-terminal ethylenediamine peptides I (R = H). Peptide I [X = D-Tyr(Et), X1 = Ile, X2 = Pro-Arg, R = H-Arg] exhibits a 2-fold enhancement of anti-V32 potency relative to its Val4 counterpart I (X, X2, R = same, X1 = Val). The retro modified peptides I [X = D-Tyr(Et), X1 = Ile, X2 = Pro-Arg-Gly, R = H-Val, H-D-Val], which possess extensions at the C-terminal, also exhibit good retention of V2 antagonism. Many of these retro substituted peptides are as potent as the most potent V2 antagonists reported to date. Some of these may be orally active. These findings point to the usefulness of ethylenediamine retro modifications in the design of AVP antagonists. Furthermore, they provide useful clues to the design of more potent and selective AVP antagonists and novel photoaffinity and radioiodinated ligands as probes of AVP receptors.
IT **143346-52-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiantidiuretic and antivasopressor activities of)
RN 143346-52-5 HCAPLUS
CN L-Cysteinamide, O-ethyl-N-[(1-mercaptocyclohexyl)acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-N-[2-[(N2-L-arginyl-L-arginyl)amino]ethyl]-, cyclic (1→5)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **143346-75-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deblocking, and disulfide cyclization of)
RN 143346-75-2 HCAPLUS
CN L-Cysteinamide, O-ethyl-N-[[1-[(phenylmethyl)thio]cyclohexyl]acetyl]-D-tyrosyl-L-phenylalanyl-L-valyl-L-asparaginyl-N-[2-[[N5-[imino[[(4-methylphenyl)sulfonyl]amino]methyl]-N2-[N5-[imino[[(4-methylphenyl)sulfonyl]amino]methyl]-N2-[(phenylmethoxy)carbonyl]-L-ornithyl]-L-ornithyl]amino]ethyl]-S-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

L13 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1991:450306 HCAPLUS
DOCUMENT NUMBER: 115:50306
ORIGINAL REFERENCE NO.: 115:8765a,8768a
TITLE: Preparation of a new vasopresin analog as a memory enhancer
INVENTOR(S): Barth, Tomislav; Hrbas, Pavel; Kluh, Ivan; Skopkova, Jana; Krojidlo, Milan
PATENT ASSIGNEE(S): Czech.
SOURCE: Czech., 6 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 268463	B1	19900314	CS 1988-4752	19880701

PRIORITY APPLN. INFO.: CS 1988-4752 19880701
GI



I



II

AB A new vasopressin analog (I) is prepared by treating (8-D-arginine)deaminovasopressin (II) by chymotrypsin. A mixture of II and chymotrypsin in 0.02M Na phosphate buffer pH 7.2 was incubated 4 h at 37°, the reaction terminated by acidifying to pH 3, the product was freeze-dried, redissolved in 2 mL H2O, and the residual II removed from I by HPLC. In a passive avoidance test in mice, 5 g I/kg s.c. gave retention times after 1 and 2 wk of 165 and 133 s, resp. vs. 125 and 78 s, resp. for II.

IT **134870-53-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as memory enhancer)
RN 134870-53-4 HCAPLUS
CN Vasopressin, [seco-2/3]- 1-(3-mercaptopropanoic acid)-8-D-arginine- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L13 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1991:401690 HCAPLUS
DOCUMENT NUMBER: 115:1690
ORIGINAL REFERENCE NO.: 115:351a,354a
TITLE: Acyclic 'seco-analogs' of atrial natriuretic peptides have biological activity in vitro: structure-activity relationships
AUTHOR(S): Bovy, P. R.; O'Neal, J. M.; Olins, G. M.; Patton, D. R.; McMahon, E. G.; Palomo, M. A.; Toren, P.; Kolodziej, E. W.
CORPORATE SOURCE: G. D. Searle and Co., St. Louis, MO, 63198, USA
SOURCE: Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 11th (1990), Meeting Date 1989, 254-7. Editor(s): Rivier, Jean E.; Marshall, Garland R. ESCOM Sci. Pub.: Leiden, Neth.
CODEN: 56XTA7
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I

AB A symposium report on the relative vasorelaxant activity (rabbit aorta) and relative binding affinities (rabbit lung membranes) of atrial natriuretic peptide (ANP) acyclic seco analogs, e.g. I. The data confirm the important role of Leu117 and Arg109 and/or Ile110 in recognition of the cyclase-coupled AnP receptor and indicate that the cyclic structure of ANP participates to stabilize the receptor-hormone complex.
IT **134302-70-8**
RL: BIOL (Biological study)
(vasorelaxant and receptor-binding activities of)
RN 134302-70-8 HCAPLUS
CN L-Aspartic acid, L-arginyl-L-phenylalanyl-L-seryl-L-asparaginyl-L-cysteinylglycyl-L-leucylglycyl-L-seryl-L-glutaminyl-L-alanylglycylglycyl-L-isoleucyl-L-arginyl-, (5→1')-disulfide with L-cysteinyl-L-phenylalanine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L13 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1986:15082 HCAPLUS
DOCUMENT NUMBER: 104:15082
ORIGINAL REFERENCE NO.: 104:2469a,2472a
TITLE: Pressinoic acid, its substituted amino acid derivatives and homologs of the D configuration, N- and C-terminal substituted derivatives and their therapeutic, biological and immunological uses
INVENTOR(S): Chauveau, Jacques; Delaage, Michel
PATENT ASSIGNEE(S): Immunotech S. A., Fr.
SOURCE: Fr. Demande, 8 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2554347	A1	19850510	FR 1983-17768	19831107
FR 2554347	B1	19861003		
PRIORITY APPLN. INFO.:			FR 1983-17768	19831107

AB The antidiuretic effect of pressinoic acid [35748-51-7] is examined Thus, pressinoic acid, when injected into a rabbit or rat at a dosage of 0.1 ng/kg, produced a slowing down of diuresis. The effect reached a maximum at 1.0 ng/kg and, at 50 ng/kg, pressinoic acid exhibited a slight pressor effect but no toxicity.

IT **99540-99-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antidiuretic activity of)

RN 99540-99-5 HCAPLUS
CN L-Cysteine, N-(3-carboxy-1-oxopropyl)-L-cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-, cyclic (1→6)-disulfide, (1→1')-amide with glycyl-L-tyrosine (9CI) (CA INDEX NAME)

PAGE 1-A





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1985:185471 HCAPLUS
DOCUMENT NUMBER: 102:185471
ORIGINAL REFERENCE NO.: 102:29117a,29120a
TITLE: Total synthesis of urogastrone (human epidermal growth factor, h-EGF)
AUTHOR(S): Hagiwara, Daijiro; Neya, Masahiro; Miyazaki, Yoshio; Hemmi, Keiji; Hashimoto, Masashi
CORPORATE SOURCE: Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan
SOURCE: Journal of the Chemical Society, Chemical Communications (1984), (24), 1676-8
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Urogastrone was prepared from 10 peptides by the segment condensation method in solution using the maximum protection strategy.
IT **96238-66-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 96238-66-3 HCAPLUS
CN L-Cysteine, glycyl-L-glutaminyl-L-arginyl-, (4→2')-disulfide with L-asparaginyl-L-cysteine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L13 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1980:42370 HCAPLUS
DOCUMENT NUMBER: 92:42370
ORIGINAL REFERENCE NO.: 92:7085a
TITLE: The preparation and metabolic fate of tritiated Nα-acetyl[2-O-methyltyrosine]oxytocin, an inhibitor of the uterotonic action of oxytocin
AUTHOR(S): Bojanovska, Vera; Barth, Tomislav; Cerny, Bohuslav; Hauzer, Karel; Jost, Karel
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Czech. Acad. Sci., Prague, 166 10/6, Czech.
SOURCE: Collection of Czechoslovak Chemical Communications (1979), 44(9), 2702-9
CODEN: CCCCAK; ISSN: 0366-547X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The title compound (I) (sp. activity 3-7 Ci/mmol) was prepared by acylating [Tyr(Me)2]-oxytocin with (CH2TCO)2O. I was stable in human pregnancy serum. Chymotrypsin cleaved I at the Tyr(Me)-Ile and Leu-Gly peptide bonds. The incubation of I with subcellular fractions of rat uterine homogenates gave fragments which appeared to be identical with the products from the chymotryptic cleavage.
IT **72289-64-6P** **72302-84-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by cleavage of oxytocin derivative with chymotrypsin)
RN 72289-64-6 HCAPLUS
CN L-Leucine, L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-, (4→1')-disulfide with N-acetyl-L-cysteinyl-O-methyl-L-tyrosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 72302-84-2 HCAPLUS
CN Glycinamide, L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucyl-, (4→1')-disulfide with N-acetyl-L-cysteinyl-O-methyl-L-tyrosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      86.03     813.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -11.05     -22.95

FILE 'STNGUIDE' ENTERED AT 15:47:11 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 12, 2010 (20100312/UP).

=> d que stat
L12          18 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC/SQEP
L13          13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12


=> d his full

     (FILE 'HOME' ENTERED AT 15:28:28 ON 16 MAR 2010)

     FILE 'REGISTRY' ENTERED AT 15:28:52 ON 16 MAR 2010
L1         12915 SEA ABB=ON  PLU=ON  KNNE/SQSP
L2            15 SEA ABB=ON  PLU=ON  L1 AND SQL<=10

     FILE 'HCAPLUS' ENTERED AT 15:29:41 ON 16 MAR 2010
L3            11 SEA ABB=ON  PLU=ON  L2
                 D L3 IBIB ABS HITSTR 1-11

     FILE 'REGISTRY' ENTERED AT 15:30:34 ON 16 MAR 2010
L4            78 SEA ABB=ON  PLU=ON  L1 AND SQL<=20

     FILE 'HCAPLUS' ENTERED AT 15:30:54 ON 16 MAR 2010
L5             3 SEA ABB=ON  PLU=ON  L4 AND (PD<19980101)
                 D L5 IBIB ABS HITSTR 1-3

     FILE 'REGISTRY' ENTERED AT 15:33:27 ON 16 MAR 2010

     FILE 'REGISTRY' ENTERED AT 15:40:10 ON 16 MAR 2010
L6               STRUCTURE UPLOADED
                 DIS
L7             0 SEA SSS FUL L6
L8               STRUCTURE UPLOADED
                 DIS
L9             0 SEA SSS FUL L8
L10              STRUCTURE UPLOADED
L11            0 SEA SSS FUL L10

     FILE 'REGISTRY' ENTERED AT 15:43:06 ON 16 MAR 2010
L12          18 SEA ABB=ON  PLU=ON  NC/SQEP

     FILE 'HCAPLUS' ENTERED AT 15:43:46 ON 16 MAR 2010
L13          13 SEA ABB=ON  PLU=ON  L12
```

D L13 IBIB ABS HITSTR 1-13

FILE 'STNGUIDE' ENTERED AT 15:47:11 ON 16 MAR 2010
D QUE STAT

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2010 HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES: 15 MAR 2010 HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE HCAPLUS

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE

```
     FILE CONTAINS CURRENT INFORMATION.
     LAST RELOADED: Mar 12, 2010 (20100312/UP).

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.05     815.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -22.95

FILE 'REGISTRY' ENTERED AT 15:56:28 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s LENC./SQSP
L14       7883 LENC./SQSP

=> L14 AND SQL<=10
        852353 SQL<=10
L15         18 L14 AND SQL<=10

=> FIL HCAP
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      38.84     853.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -22.95

FILE 'HCAPLUS' ENTERED AT 15:57:17 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> L15
L16 5 L15

=> D L16 IBIB ABS HITSTR 1-5

L16 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1101939 HCAPLUS
DOCUMENT NUMBER: 151:334264
TITLE: Nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer
INVENTOR(S): Challita-Eid, Pia M.; Raitano, Arthur B.; Faris, Mary; Hubert, Rene S.; Morrison, Karen Jane Meyrick; Jakobovits, Aya
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: U.S., 234pp., Cont.-in-part of U.S. Ser. No. 121,024. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 34
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7585505	B2	20090908	US 2005-97864	20050401
US 20050265924	A1	20051201		
EP 1854809	A1	20071114	EP 2007-101693	20010822
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 20030191073	A1	20031009	US 2001-5480	20011107
US 20030165505	A1	20030904	US 2002-62109	20020131
US 7067130	B2	20060627		
CA 2479049	A1	20031016	CA 2002-2479049	20020401
CA 2480811	A1	20031016	CA 2002-2480811	20020401
WO 2003085081	A2	20031016	WO 2002-US10132	20020401
WO 2003085081	A3	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003085121	A2	20031016	WO 2002-US10220	20020401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002258688	A1	20031020	AU 2002-258688	20020401
AU 2002258688	B2	20080814		
AU 2002258689	A1	20031020	AU 2002-258689	20020401
AU 2002258689	B2	20070816		
EP 1553980	A2	20050720	EP 2002-728645	20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, FI, CY, TR				
EP 1578980	A2	20050928	EP 2002-728647		20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EP 1790662	A1	20070530	EP 2007-1331		20020409
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR					
US 20070031335	A1	20070208	US 2002-121024		20020410
US 20060002993	A1	20060105	US 2004-859643		20040602
US 7279556	B2	20071009			
US 20070004913	A1	20070104	US 2004-860769		20040602
US 7405290	B2	20080729			
US 20050227253	A1	20051013	US 2004-990137		20041115
US 20060018917	A1	20060126	US 2004-989767		20041115
US 20050214211	A1	20050929	US 2005-73349		20050303
US 20070048283	A1	20070301	US 2005-154298		20050615
US 7641905	B2	20100105			
US 20070041968	A1	20070222	US 2005-156231		20050617
US 20070048299	A1	20070301	US 2005-155906		20050617
US 7628989	B2	20091208			
US 20070054284	A1	20070308	US 2006-368284		20060302
US 7592149	B2	20090922			
US 20080280822	A1	20081113	US 2006-442031		20060526
US 7642342	B2	20100105			
US 20070212299	A1	20070913	US 2007-655822		20070119
US 7667018	B2	20100223			
US 20080233598	A1	20080925	US 2007-704092		20070206
AU 2007201354	A1	20070419	AU 2007-201354		20070326
JP 2007254490	A	20071004	JP 2007-168300		20070626
JP 4177877	B2	20081105			
US 20090264381	A1	20091022	US 2007-833918		20070803
US 7667015	B2	20100223			
AU 2007237282	A1	20071220	AU 2007-237282		20071130
JP 2008188015	A	20080821	JP 2008-43368		20080225
JP 4299872	B2	20090722			
AU 2008246215	A1	20081204	AU 2008-246215		20081114
US 20090148854	A1	20090611	US 2009-357154		20090121
PRIORITY APPLN. INFO.:			US 2001-282739P	P	20010410
			US 2001-283112P	P	20010410
			US 2001-286630P	P	20010425
			US 2001-5480	B1	20011107
			US 2002-62109	A1	20020131
			US 2002-121024	A2	20020410
			US 2000-227098P	P	20000822
			US 2001-300373P	P	20010622
			EP 2001-964345	A3	20010822
			US 2001-935430	A1	20010822
			AU 2002-258688	A3	20020401
			WO 2002-US10132	W	20020401
			WO 2002-US10220	W	20020401
			AU 2002-305169	A3	20020409
			EP 2002-762038	A3	20020409
			US 2002-120835	A3	20020409
			US 2002-120885	B1	20020409
			US 2002-120901	A1	20020409
			US 2002-120907	B3	20020409
			AU 2002-361610	A3	20021107

JP 2003-542587	A3	20021107
US 2002-291241	A3	20021107
US 2005-73349	B1	20050303
US 2006-368284	A1	20060302
JP 2007-168300	A3	20070626

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers of the breast, colon, kidney, lung, ovary, pancreas, and prostate. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic, and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.

IT **525539-81-5** **525540-99-2** **525542-96-5** **528836-14-8**
RL: PRP (Properties)
(unclaimed sequence; nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer)

RN 525539-81-5 HCAPLUS

CN L-Valine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 525540-99-2 HCAPLUS

CN L-Alanine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 525542-96-5 HCAPLUS
CN L-Valine, L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 528836-14-8 HCAPLUS
CN L-Arginine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT:	71	THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:853968 HCAPLUS
DOCUMENT NUMBER: 149:167940
TITLE: Peptide modulators of angiogenesis and their use for treatment of cancer
INVENTOR(S): Popel, Aleksander S.
PATENT ASSIGNEE(S): The Johns Hopkins University, USA
SOURCE: PCT Int. Appl., 169pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008085828	A2	20080717	WO 2008-US36	20080103
WO 2008085828	A3	20081120		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-878579P P 20070103

AB Peptides containing a TSP, CXC, collagen, somatotropin, or serpin motif as well as addnl. peptides derived from placental lactogen, caspase 10, etc., are disclosed. These peptides may be used to inhibit blood vessel formation, e.g., in treatment of tumors. Thus, a systematic computational methodol. based on bioinformatics was used to identify novel peptide modulators of angiogenesis that were characterized in vitro and/or in vivo.

IT **1039155-66-2**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide modulators of angiogenesis and their use for treatment of cancer)

RN 1039155-66-2 HCAPLUS
CN L-Leucine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:411968 HCAPLUS
DOCUMENT NUMBER: 148:447879
TITLE: Polynucleotide vaccines encoding CTL and/or HTL epitopes for inducing cellular immune responses against influenza virus infection
INVENTOR(S): Alexander, Jeffery L.; Southwood, Scott F.; Bilsel, Pamuk A.; Newman, Mark J.
PATENT ASSIGNEE(S): Pharmexa Inc., USA
SOURCE: PCT Int. Appl., 313 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008039267	A2	20080403	WO 2007-US16529	20070723
WO 2008039267	A3	20081231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007300663	A1	20080403	AU 2007-300663	20070723
CA 2658559	A1	20080403	CA 2007-2658559	20070723
EP 2069376	A2	20090617	EP 2007-861332	20070723
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-832112P P 20060721
WO 2007-US16529 W 20070723
OTHER SOURCE(S): MARPAT 148:447879
AB This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare influenza virus epitopes, and to develop epitope-based vaccines directed towards influenza virus. These epitopes are cytotoxic T lymphocyte epitopes, helper T lymphocyte epitopes and B cell epitopes derived from influenza virus hemagglutinin, neuraminidase, nucleoprotein, RNA polymerase subunit PA, RNA polymerase basic protein 1, RNA polymerase basic protein 2, nonstructural gene 1, nonstructural gene 2, matrix protein 1 or matrix protein 2. More specifically, this application communicates our discovery of pharmaceutical compns. and methods of use in the prevention and treatment of influenza virus infection.
IT **1017870-02-8**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polynucleotide vaccines encoding CTL and/or HTL epitopes for inducing cellular immune responses against influenza virus infection)

RN 1017870-02-8 HCAPLUS
CN L-Glutamine, L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-α-glutamyl-L-threonyl-L-lysyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L16 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:377029 HCAPLUS
DOCUMENT NUMBER: 138:400512
TITLE: Nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer
INVENTOR(S): Jakobovits, Aya; Raitano, Arthur B.; Faris, Mary; Hubert, Rene S.; Ge, Wangmao; Morrison, Karen Jane Meyrick; Morrison, Robert Kendall; Challita-Eid, Pia M.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 34
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040340	A2	20030515	WO 2002-US36002	20021107
WO 2003040340	A9	20030807		
WO 2003040340	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030191073	A1	20031009	US 2001-5480	20011107
US 20030165505	A1	20030904	US 2002-62109	20020131
US 7067130	B2	20060627		
CA 2479049	A1	20031016	CA 2002-2479049	20020401
CA 2480811	A1	20031016	CA 2002-2480811	20020401
WO 2003085081	A2	20031016	WO 2002-US10132	20020401
WO 2003085081	A3	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003085121	A2	20031016	WO 2002-US10220	20020401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002258688	A1	20031020	AU 2002-258688	20020401
AU 2002258688	B2	20080814		
AU 2002258689	A1	20031020	AU 2002-258689	20020401
AU 2002258689	B2	20070816		
EP 1553980	A2	20050720	EP 2002-728645	20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1578980	A2	20050928	EP 2002-728647	20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2462653	A1	20030515	CA 2002-2462653	20021107
AU 2002361610	A1	20030519	AU 2002-361610	20021107
AU 2002361610	A2	20030519		
AU 2002361610	B2	20070111		
EP 1537140	A2	20050608	EP 2002-797088	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
JP 2006509492	T	20060323	JP 2003-542587	20021107
JP 4200100	B2	20081224		
US 20060002993	A1	20060105	US 2004-859643	20040602
US 7279556	B2	20071009		
US 20070004913	A1	20070104	US 2004-860769	20040602
US 7405290	B2	20080729		
US 20050265921	A1	20051201	US 2005-97912	20050401
US 7655234	B2	20100202		
US 20070212299	A1	20070913	US 2007-655822	20070119
US 7667018	B2	20100223		
AU 2007201354	A1	20070419	AU 2007-201354	20070326
JP 2007254490	A	20071004	JP 2007-168300	20070626
JP 4177877	B2	20081105		
AU 2007237282	A1	20071220	AU 2007-237282	20071130
JP 2008188015	A	20080821	JP 2008-43368	20080225
JP 4299872	B2	20090722		
AU 2008246215	A1	20081204	AU 2008-246215	20081114
PRIORITY APPLN. INFO.:			US 2001-5480 A	20011107
			US 2002-62109 A	20020131
			AU 2002-258688 A3	20020401
			WO 2002-US10132 W	20020401
			WO 2002-US10220 W	20020401
			AU 2002-305169 A3	20020409
			AU 2002-361610 A3	20021107
			JP 2003-542587 A3	20021107
			US 2002-291241 A3	20021107
			WO 2002-US36002 W	20021107
			JP 2007-168300 A3	20070626

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue-specific expression in normal adult tissue, and is aberrantly over-expressed in several cancers. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene is 100% identical to a previously cloned and sequenced gene, namely ectonucleotide pyrophosphatase/phosphodiesterase 3, also known as phosphodiesterase-Iβ, gp130RB13-6, E-NNP3 (ENPP3), PDNP3,

and DC203c. The 161P2F10B gene of fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

IT **525539-81-5** **525540-99-2** **525542-96-5**
525544-34-7 **525548-96-3** **525550-81-6**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epitope peptide; nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer)

RN 525539-81-5 HCAPLUS
CN L-Valine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 525540-99-2 HCAPLUS
CN L-Alanine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 525542-96-5 HCAPLUS
CN L-Valine, L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525544-34-7 HCAPLUS
CN L-Arginine, L-seryl-L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525548-96-3 HCAPLUS
CN L-Cysteine, L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525550-81-6 HCAPLUS
CN L-Cysteine, L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

IT **528836-14-8**
RL: PRP (Properties)
(unclaimed sequence; nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer)
RN 528836-14-8 HCAPLUS
CN L-Arginine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L16 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:923846 HCAPLUS
DOCUMENT NUMBER: 136:65232
TITLE: 55P4H4 protein and gene expressed in various human cancers
INVENTOR(S): Faris, Mary; Hubert, Rene S.; Afar, Daniel E. H.; Levin, Elana; Mitchell, Steven Chappell; Raitano, Arthur B.; Jakobovits, Aya
PATENT ASSIGNEE(S): Urogenesys, Inc., USA
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001096391	A2	20011220	WO 2001-US19246		20010613
WO 2001096391	A3	20021205			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1294875	A2	20030326	EP 2001-946410		20010613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 20030064418	A1	20030403	US 2001-881636		20010613
PRIORITY APPLN. INFO.:			US 2000-211454P	P	20000613
			WO 2001-US19246	W	20010613

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A novel human gene (designated 55P4H4) and its encoded protein are described. Protein 55P4H4 shows sequence homologies to human hypoxia-regulated gene products, murine RIK, Drosophila CHARBYE, and yeast RIC1 proteins. While 55P4H4 exhibits tissue-restricted expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, lung, testis, bone, cervical, brain, and ovarian cancers. The gene is mapped to human chromosome 4q22.3-24, a region known to be associated with a variety of chromosomal abnormalities in a number of different cancers. Consequently, 55P4H4 provides a diagnostic and/or therapeutic target for cancers, and the 55P4H4 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.

IT **382602-56-4** **382602-59-7** **382602-95-1**
382603-33-0 **382603-79-4** **382603-90-9**
382603-94-3 **382604-28-6** **383126-20-3**
RL: PRP (Properties)
(unclaimed sequence; 55P4H4 protein and gene expressed in various human cancers)

RN 382602-56-4 HCAPLUS
CN L-Serine, L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 382602-59-7 HCAPLUS
CN L-Lysine, L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH2

RN 382602-95-1 HCAPLUS
CN L-Lysine, L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 382603-33-0 HCAPLUS
CN L-Lysine, L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH2

RN 382603-79-4 HCAPLUS
CN L-Leucine, L-leucyl-L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 382603-90-9 HCAPLUS
CN L-Leucine, L-asparaginyl-L-leucyl-L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 382603-94-3 HCAPLUS
CN L-Serine, L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 382604-28-6 HCAPLUS

CN L-Lysine, L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 383126-20-3 HCAPLUS
CN L-Serine, L-leucyl-L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      34.87     888.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.25     -27.20

FILE 'REGISTRY' ENTERED AT 15:58:17 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> L14 AND SQL<=20
       4969317 SQL<=20
L17         24 L14 AND SQL<=20

=> FIL HCAP
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.99     894.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -27.20

FILE 'HCAPLUS' ENTERED AT 15:58:32 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
```

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> L17
L18 6 L17

=> D L18 IBIB ABS HITSTR 1-6

L18 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1101939 HCAPLUS
DOCUMENT NUMBER: 151:334264
TITLE: Nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer
INVENTOR(S): Challita-Eid, Pia M.; Raitano, Arthur B.; Faris, Mary; Hubert, Rene S.; Morrison, Karen Jane Meyrick; Jakobovits, Aya
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: U.S., 234pp., Cont.-in-part of U.S. Ser. No. 121,024. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 34
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7585505	B2	20090908	US 2005-97864	20050401
US 20050265924	A1	20051201		
EP 1854809	A1	20071114	EP 2007-101693	20010822
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 20030191073	A1	20031009	US 2001-5480	20011107
US 20030165505	A1	20030904	US 2002-62109	20020131
US 7067130	B2	20060627		
CA 2479049	A1	20031016	CA 2002-2479049	20020401
CA 2480811	A1	20031016	CA 2002-2480811	20020401
WO 2003085081	A2	20031016	WO 2002-US10132	20020401
WO 2003085081	A3	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003085121	A2	20031016	WO 2002-US10220	20020401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002258688	A1	20031020	AU 2002-258688	20020401
AU 2002258688	B2	20080814		
AU 2002258689	A1	20031020	AU 2002-258689	20020401
AU 2002258689	B2	20070816		
EP 1553980	A2	20050720	EP 2002-728645	20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, FI, CY, TR				
EP 1578980		A2	20050928	EP 2002-728647	20020401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1790662		A1	20070530	EP 2007-1331	20020409
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 20070031335		A1	20070208	US 2002-121024	20020410
US 20060002993		A1	20060105	US 2004-859643	20040602
US 7279556		B2	20071009		
US 20070004913		A1	20070104	US 2004-860769	20040602
US 7405290		B2	20080729		
US 20050227253		A1	20051013	US 2004-990137	20041115
US 20060018917		A1	20060126	US 2004-989767	20041115
US 20050214211		A1	20050929	US 2005-73349	20050303
US 20070048283		A1	20070301	US 2005-154298	20050615
US 7641905		B2	20100105		
US 20070041968		A1	20070222	US 2005-156231	20050617
US 20070048299		A1	20070301	US 2005-155906	20050617
US 7628989		B2	20091208		
US 20070054284		A1	20070308	US 2006-368284	20060302
US 7592149		B2	20090922		
US 20080280822		A1	20081113	US 2006-442031	20060526
US 7642342		B2	20100105		
US 20070212299		A1	20070913	US 2007-655822	20070119
US 7667018		B2	20100223		
US 20080233598		A1	20080925	US 2007-704092	20070206
AU 2007201354		A1	20070419	AU 2007-201354	20070326
JP 2007254490		A	20071004	JP 2007-168300	20070626
JP 4177877		B2	20081105		
US 20090264381		A1	20091022	US 2007-833918	20070803
US 7667015		B2	20100223		
AU 2007237282		A1	20071220	AU 2007-237282	20071130
JP 2008188015		A	20080821	JP 2008-43368	20080225
JP 4299872		B2	20090722		
AU 2008246215		A1	20081204	AU 2008-246215	20081114
US 20090148854		A1	20090611	US 2009-357154	20090121
PRIORITY APPLN. INFO.:				US 2001-282739P	P 20010410
				US 2001-283112P	P 20010410
				US 2001-286630P	P 20010425
				US 2001-5480	B1 20011107
				US 2002-62109	A1 20020131
				US 2002-121024	A2 20020410
				US 2000-227098P	P 20000822
				US 2001-300373P	P 20010622
				EP 2001-964345	A3 20010822
				US 2001-935430	A1 20010822
				AU 2002-258688	A3 20020401
				WO 2002-US10132	W 20020401
				WO 2002-US10220	W 20020401
				AU 2002-305169	A3 20020409
				EP 2002-762038	A3 20020409
				US 2002-120835	A3 20020409
				US 2002-120885	B1 20020409
				US 2002-120901	A1 20020409
				US 2002-120907	B3 20020409
				AU 2002-361610	A3 20021107

JP 2003-542587	A3	20021107
US 2002-291241	A3	20021107
US 2005-73349	B1	20050303
US 2006-368284	A1	20060302
JP 2007-168300	A3	20070626

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers of the breast, colon, kidney, lung, ovary, pancreas, and prostate. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic, and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.

IT **525539-81-5** **525540-99-2** **525542-96-5**
528836-14-8
RL: PRP (Properties)
(unclaimed sequence; nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer)

RN 525539-81-5 HCAPLUS

CN L-Valine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 525540-99-2 HCAPLUS

CN L-Alanine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 525542-96-5 HCAPLUS
CN L-Valine, L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 528836-14-8 HCAPLUS
CN L-Arginine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT:	71	THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:853968 HCAPLUS
DOCUMENT NUMBER: 149:167940
TITLE: Peptide modulators of angiogenesis and their use for treatment of cancer
INVENTOR(S): Popel, Aleksander S.
PATENT ASSIGNEE(S): The Johns Hopkins University, USA
SOURCE: PCT Int. Appl., 169pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008085828	A2	20080717	WO 2008-US36	20080103
WO 2008085828	A3	20081120		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-878579P P 20070103

AB Peptides containing a TSP, CXC, collagen, somatotropin, or serpin motif as well as addnl. peptides derived from placental lactogen, caspase 10, etc., are disclosed. These peptides may be used to inhibit blood vessel formation, e.g., in treatment of tumors. Thus, a systematic computational methodol. based on bioinformatics was used to identify novel peptide modulators of angiogenesis that were characterized in vitro and/or in vivo.

IT **1039155-66-2**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide modulators of angiogenesis and their use for treatment of cancer)

RN 1039155-66-2 HCAPLUS
CN L-Leucine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.


CO2H
O
i-Bu
S
N
H
R
H
N
O
HS
S
O
N
H
S
CO2H
H2N
O
HN
O
O
H2N
N
H
S
Bu-i

L18 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:411968 HCAPLUS
DOCUMENT NUMBER: 148:447879
TITLE: Polynucleotide vaccines encoding CTL and/or HTL epitopes for inducing cellular immune responses against influenza virus infection
INVENTOR(S): Alexander, Jeffery L.; Southwood, Scott F.; Bilsel, Pamuk A.; Newman, Mark J.
PATENT ASSIGNEE(S): Pharmexa Inc., USA
SOURCE: PCT Int. Appl., 313 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008039267	A2	20080403	WO 2007-US16529	20070723
WO 2008039267	A3	20081231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007300663	A1	20080403	AU 2007-300663	20070723
CA 2658559	A1	20080403	CA 2007-2658559	20070723
EP 2069376	A2	20090617	EP 2007-861332	20070723
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-832112P P 20060721
WO 2007-US16529 W 20070723
OTHER SOURCE(S): MARPAT 148:447879
AB This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare influenza virus epitopes, and to develop epitope-based vaccines directed towards influenza virus. These epitopes are cytotoxic T lymphocyte epitopes, helper T lymphocyte epitopes and B cell epitopes derived from influenza virus hemagglutinin, neuraminidase, nucleoprotein, RNA polymerase subunit PA, RNA polymerase basic protein 1, RNA polymerase basic protein 2, nonstructural gene 1, nonstructural gene 2, matrix protein 1 or matrix protein 2. More specifically, this application communicates our discovery of pharmaceutical compns. and methods of use in the prevention and treatment of influenza virus infection.
IT **1017869-31-6** **1017869-33-8** **1017870-02-8**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polynucleotide vaccines encoding CTL and/or HTL epitopes for inducing cellular immune responses against influenza virus infection)

RN 1017869-31-6 HCAPLUS
CN L-Threonine, L-serylglycyl-L-isoleucyl-L-methionyl-L-lysyl-L-threonyl-L-α-glutamylglycyl-L-threonyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-α-glutamyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 1017869-33-8 HCAPLUS
CN L-Leucine, L-α-glutamylglycyl-L-threonyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-α-glutamyl-L-threonyl-L-lysyl-L-

cysteinyl-L-glutaminyl-L-threonyl-L-prolyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 1017870-02-8 HCAPLUS
CN L-Glutamine, L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-α-glutamyl-L-threonyl-L-lysyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L18 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:377029 HCAPLUS
DOCUMENT NUMBER: 138:400512
TITLE: Nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer
INVENTOR(S): Jakobovits, Aya; Raitano, Arthur B.; Faris, Mary; Hubert, Rene S.; Ge, Wangmao; Morrison, Karen Jane Meyrick; Morrison, Robert Kendall; Challita-Eid, Pia M.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 34
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040340	A2	20030515	WO 2002-US36002	20021107
WO 2003040340	A9	20030807		
WO 2003040340	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030191073	A1	20031009	US 2001-5480	20011107
US 20030165505	A1	20030904	US 2002-62109	20020131
US 7067130	B2	20060627		
CA 2479049	A1	20031016	CA 2002-2479049	20020401
CA 2480811	A1	20031016	CA 2002-2480811	20020401
WO 2003085081	A2	20031016	WO 2002-US10132	20020401
WO 2003085081	A3	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003085121	A2	20031016	WO 2002-US10220	20020401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002258688	A1	20031020	AU 2002-258688		20020401
AU 2002258688	B2	20080814			
AU 2002258689	A1	20031020	AU 2002-258689		20020401
AU 2002258689	B2	20070816			
EP 1553980	A2	20050720	EP 2002-728645		20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
EP 1578980	A2	20050928	EP 2002-728647		20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CA 2462653	A1	20030515	CA 2002-2462653		20021107
AU 2002361610	A1	20030519	AU 2002-361610		20021107
AU 2002361610	A2	20030519			
AU 2002361610	B2	20070111			
EP 1537140	A2	20050608	EP 2002-797088		20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK					
JP 2006509492	T	20060323	JP 2003-542587		20021107
JP 4200100	B2	20081224			
US 20060002993	A1	20060105	US 2004-859643		20040602
US 7279556	B2	20071009			
US 20070004913	A1	20070104	US 2004-860769		20040602
US 7405290	B2	20080729			
US 20050265921	A1	20051201	US 2005-97912		20050401
US 7655234	B2	20100202			
US 20070212299	A1	20070913	US 2007-655822		20070119
US 7667018	B2	20100223			
AU 2007201354	A1	20070419	AU 2007-201354		20070326
JP 2007254490	A	20071004	JP 2007-168300		20070626
JP 4177877	B2	20081105			
AU 2007237282	A1	20071220	AU 2007-237282		20071130
JP 2008188015	A	20080821	JP 2008-43368		20080225
JP 4299872	B2	20090722			
AU 2008246215	A1	20081204	AU 2008-246215		20081114
PRIORITY APPLN. INFO.:			US 2001-5480	A	20011107
			US 2002-62109	A	20020131
			AU 2002-258688	A3	20020401
			WO 2002-US10132	W	20020401
			WO 2002-US10220	W	20020401
			AU 2002-305169	A3	20020409
			AU 2002-361610	A3	20021107
			JP 2003-542587	A3	20021107
			US 2002-291241	A3	20021107
			WO 2002-US36002	W	20021107
			JP 2007-168300	A3	20070626

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue-specific expression in normal adult tissue, and is aberrantly over-expressed in several cancers. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene is 100% identical to a previously cloned and sequenced gene, namely ectonucleotide pyrophosphatase/phosphodiesterase 3, also known as phosphodiesterase-Iβ, gp130RB13-6, E-NNP3 (ENPP3), PDNP3,

and DC203c. The 161P2F10B gene of fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

IT **525539-81-5** **525540-99-2** **525542-96-5**
525544-34-7 **525548-96-3** **525550-81-6**
525553-84-8 **525556-01-8** **525556-92-7**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epitope peptide; nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer)

RN 525539-81-5 HCAPLUS
CN L-Valine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 525540-99-2 HCAPLUS
CN L-Alanine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 525542-96-5 HCAPLUS
CN L-Valine, L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525544-34-7 HCAPLUS
CN L-Arginine, L-seryl-L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525548-96-3 HCAPLUS
CN L-Cysteine, L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525550-81-6 HCAPLUS
CN L-Cysteine, L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 525553-84-8 HCAPLUS
CN L-Alanine, L-α-aspartyl-L-alanyl-L-seryl-L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 525556-01-8 HCAPLUS
CN L-Arginine, L-lysyl-L-lysyl-L-cysteinyl-L-phenylalanyl-L-α-aspartyl-L-alanyl-L-seryl-L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 525556-92-7 HCAPLUS
CN L-Aspartic acid, L-phenylalanyl-L-arginylglycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-arginyl-L-cysteinyl-L-α-aspartyl-L-valyl-L-alanyl-L-cysteinyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



IT **528836-14-8**
RL: PRP (Properties)
(unclaimed sequence; nucleic acid and corresponding protein designated 161P2F10B useful in treatment and detection of cancer)
RN 528836-14-8 HCAPLUS
CN L-Arginine, glycyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L18 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:923846 HCAPLUS
DOCUMENT NUMBER: 136:65232
TITLE: 55P4H4 protein and gene expressed in various human cancers
INVENTOR(S): Faris, Mary; Hubert, Rene S.; Afar, Daniel E. H.; Levin, Elana; Mitchell, Steven Chappell; Raitano, Arthur B.; Jakobovits, Aya
PATENT ASSIGNEE(S): Urogenesys, Inc., USA
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001096391	A2	20011220	WO 2001-US19246		20010613
WO 2001096391	A3	20021205			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1294875	A2	20030326	EP 2001-946410		20010613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 20030064418	A1	20030403	US 2001-881636		20010613
PRIORITY APPLN. INFO.:			US 2000-211454P	P	20000613
			WO 2001-US19246	W	20010613

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A novel human gene (designated 55P4H4) and its encoded protein are described. Protein 55P4H4 shows sequence homologies to human hypoxia-regulated gene products, murine RIK, Drosophila CHARBYE, and yeast RIC1 proteins. While 55P4H4 exhibits tissue-restricted expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, lung, testis, bone, cervical, brain, and ovarian cancers. The gene is mapped to human chromosome 4q22.3-24, a region known to be associated with a variety of chromosomal abnormalities in a number of different cancers. Consequently, 55P4H4 provides a diagnostic and/or therapeutic target for cancers, and the 55P4H4 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
IT **382602-56-4** **382602-59-7** **382602-95-1**
382603-33-0 **382603-79-4** **382603-90-9**
382603-94-3 **382604-28-6** **383126-20-3**
RL: PRP (Properties)
(unclaimed sequence; 55P4H4 protein and gene expressed in various human cancers)
RN 382602-56-4 HCAPLUS
CN L-Serine, L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 382602-59-7 HCAPLUS
CN L-Lysine, L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH2

RN 382602-95-1 HCAPLUS
CN L-Lysine, L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 382603-33-0 HCAPLUS
CN L-Lysine, L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH2

RN 382603-79-4 HCAPLUS
CN L-Leucine, L-leucyl-L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 382603-90-9 HCAPLUS
CN L-Leucine, L-asparaginyl-L-leucyl-L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 382603-94-3 HCAPLUS
CN L-Serine, L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 382604-28-6 HCAPLUS

CN L-Lysine, L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl-L-seryl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 383126-20-3 HCAPLUS
CN L-Serine, L-leucyl-L-valyl-L-lysyl-L-methionyl-L-leucyl-L-α-glutamyl-L-asparaginyl-L-cysteinyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1975:51839 HCAPLUS
DOCUMENT NUMBER: 82:51839
ORIGINAL REFERENCE NO.: 82:8222h,8223a
TITLE: Biological activity and the binding affinity of modified insulins determined on isolated rat fat cells
AUTHOR(S): Gleimann, J.; Gammeltoft, S.
CORPORATE SOURCE: Inst. Med. Physiol. C, Univ. Copenhagen, Copenhagen, Den.
SOURCE: Diabetologia (1974), 10(2), 105-13
CODEN: DBTGAJ; ISSN: 0012-186X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The insulin analogs, 26B-30B-dependapeptide-insulin [52499-33-9], 1A-deglycine-insulin [52627-23-3] 1B-deamine-insulin [52499-38-4] and 1A,1B-diphenylthiocarbamoyl-insulin [**52499-62-4**] exerted the same maximal effect on the conversion of glucose [50-99-7] into lipids as native insulin [9004-10-8] in isolated rat fat cells. Removal of 2 amino acids from the N-terminal end of the B chain caused little decrease in potency (the concentration required for a modified insulin to produce 1/2 of the maximal effect as compared to the concentration required for insulin). In contrast, removal of glycine from the N-terminal end of the A chain decreased the potency by 99%. The potency of the modified insulin substituted with acetyl or succinyl residues at position A1 was less than that at position B1 or B29. Cross linkage between positions A1 and B29 decreased the potency to 2-10%, whereas that between A1 and B1 almost abolished the activity. Of 9 modified insulins tested for their effect on insulin-125I binding to fat cell receptor sites, all inhibited the binding and the inhibition increased with decreasing biol. potency. The binding affinity of insulin, and therefore the potency, appears to be dependent on an intact tertiary structure of insulin and a free access to the N-terminal end of the A chain.
IT **52499-62-4**
RL: BIOL (Biological study)
(lipid formation stimulation by, in adipose tissue)
RN 52499-62-4 HCAPLUS
CN Insulin (cattle), NA-[(diphenylamino)thioxomethyl]-NB-[(diphenylamino)thioxomethyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      35.45     930.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.10     -32.30

FILE 'STNGUIDE' ENTERED AT 15:59:21 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 12, 2010 (20100312/UP).

=> d que stat
L14         7883 SEA FILE=REGISTRY ABB=ON  PLU=ON  LENC./SQSP
L17           24 SEA FILE=REGISTRY ABB=ON  PLU=ON  L14 AND SQL<=20
L18            6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17


=> d his full

     (FILE 'HOME' ENTERED AT 15:28:28 ON 16 MAR 2010)

     FILE 'REGISTRY' ENTERED AT 15:28:52 ON 16 MAR 2010
L1         12915 SEA ABB=ON  PLU=ON  KNNE/SQSP
L2            15 SEA ABB=ON  PLU=ON  L1 AND SQL<=10

     FILE 'HCAPLUS' ENTERED AT 15:29:41 ON 16 MAR 2010
L3            11 SEA ABB=ON  PLU=ON  L2
                 D L3 IBIB ABS HITSTR 1-11

     FILE 'REGISTRY' ENTERED AT 15:30:34 ON 16 MAR 2010
L4            78 SEA ABB=ON  PLU=ON  L1 AND SQL<=20

     FILE 'HCAPLUS' ENTERED AT 15:30:54 ON 16 MAR 2010
L5             3 SEA ABB=ON  PLU=ON  L4 AND (PD<19980101)
                 D L5 IBIB ABS HITSTR 1-3

     FILE 'REGISTRY' ENTERED AT 15:33:27 ON 16 MAR 2010

     FILE 'REGISTRY' ENTERED AT 15:40:10 ON 16 MAR 2010
L6               STRUCTURE UPLOADED
                 DIS
L7             0 SEA SSS FUL L6
L8               STRUCTURE UPLOADED
                 DIS
L9             0 SEA SSS FUL L8
L10              STRUCTURE UPLOADED
L11            0 SEA SSS FUL L10

     FILE 'REGISTRY' ENTERED AT 15:43:06 ON 16 MAR 2010
L12           18 SEA ABB=ON  PLU=ON  NC/SQEP

     FILE 'HCAPLUS' ENTERED AT 15:43:46 ON 16 MAR 2010
```

```
L13          13 SEA ABB=ON  PLU=ON  L12
                D L13 IBIB ABS HITSTR 1-13

     FILE 'STNGUIDE' ENTERED AT 15:47:11 ON 16 MAR 2010
                D QUE STAT

     FILE 'REGISTRY' ENTERED AT 15:56:28 ON 16 MAR 2010
L14        7883 SEA ABB=ON  PLU=ON  LENC./SQSP
L15          18 SEA ABB=ON  PLU=ON  L14 AND SQL<=10

     FILE 'HCAPLUS' ENTERED AT 15:57:17 ON 16 MAR 2010
L16           5 SEA ABB=ON  PLU=ON  L15
                D L16 IBIB ABS HITSTR 1-5

     FILE 'REGISTRY' ENTERED AT 15:58:17 ON 16 MAR 2010
L17          24 SEA ABB=ON  PLU=ON  L14 AND SQL<=20

     FILE 'HCAPLUS' ENTERED AT 15:58:32 ON 16 MAR 2010
L18           6 SEA ABB=ON  PLU=ON  L17
                D L18 IBIB ABS HITSTR 1-6

     FILE 'STNGUIDE' ENTERED AT 15:59:21 ON 16 MAR 2010
                D QUE STAT


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
     DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12
FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 12, 2010 (20100312/UP).

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.56	930.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-32.30

STN INTERNATIONAL LOGOFF AT 16:04:02 ON 16 MAR 2010